Advertisement

Vitamin K2 Administration Improves the Prognoses of Patients with Hepatocellular Carcinoma Presenting High Levels of Serum Des-γ-Carboxy Prothrombin

  • Yukihiro Koike
  • Yasushi Shiratori
  • Haruhiko Yoshida
  • Masao Omata
Conference paper

Abstract

Background: Patients with hepatocellular carcinoma frequently develop portal venous invasion, a diagnosis of which affects patient prognosis. We have already shown the close association between the development of portal venous invasion and serum des-y-carboxy prothrombin levels in patients with hepatocellular carcinoma (Figure 1) [1]. In addition, it has been reported that vitamin K2 administration decreases serum des-y-carboxy prothrombin levels in hepatocellular carcinoma patients and inhibits the proliferation of hepatocellular.
Figure 1

Incidence of Portal Venous Invasion (PVI) after local ablation of hepatocellular carcinoma

Keywords

Hepatocellular Carcinoma Hepatocellular Carcinoma Cell Viral Hepatitis Tyrosine Phosphorylation Cell Growth Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-y-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001;91:561–569.PubMedCrossRefGoogle Scholar
  2. Ni R, Nishikawa Y, Can BI. Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. J Biol Chem 1998;273:9906–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Yukihiro Koike
    • 1
  • Yasushi Shiratori
    • 1
  • Haruhiko Yoshida
    • 1
  • Masao Omata
    • 1
  1. 1.Department of GastroenterologyUniversity of Tokyo Graduate School of MedicineTokyoJapan

Personalised recommendations